CLSA Premium(06877.HK)預期19年度將錄得顯著虧損
格隆匯1月23日丨CLSA Premium(06877.HK)公佈,預期與2018年12月31日止年度錄得淨利潤相比,集團於截至2019年12月31日止年度將錄得顯著虧損。
公告稱,顯著虧損是由於集團外部客户數量鋭減,導致來自於槓桿式外匯交易和其他交易的業務收入下跌,及外匯交易波動率下降使集團客户在相關年度的交易量同步減少;各地監管機構,包括澳洲及香港,收緊有關槓桿式外匯交易的法規,導致投資者在相關年度內,重新調整他們的投資組合;及全球經濟在相關年度同步放緩,影響投資者對槓桿式外匯和商品的投資態度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.